Not to naysay: but these are very small, controlled trials on very, very specific populations with very specific inclusion criteria. Hopefully, these PD-1 inhibitors turn out to be effectively cures (with no recurrence during lifetime), but it's extremely difficult and irresponsible to assume that's what the data suggest.
A lot of follow ups post-treatment only extend out five years or so.
Yeah, I worked with a clinics startup that had some Phase III studies going for cancer treatments. Both treatments caused cytokine storms in patients that eventually got so bad they all dropped out of study.
Not to naysay: but these are very small, controlled trials on very, very specific populations with very specific inclusion criteria. Hopefully, these PD-1 inhibitors turn out to be effectively cures (with no recurrence during lifetime), but it's extremely difficult and irresponsible to assume that's what the data suggest.
A lot of follow ups post-treatment only extend out five years or so.
Yeah, I worked with a clinics startup that had some Phase III studies going for cancer treatments. Both treatments caused cytokine storms in patients that eventually got so bad they all dropped out of study.